CAMBRIDGE, ENGLAND--(BUSINESS WIRE)--
bit.bio, a synthetic biology company working on developing and providing every human cell type at scale, with the aim of transforming the research and medicine landscape, today launch their ioGlutamatergic Neurons HTT50CAG/WT cells to advance research and accelerate drug discovery for Huntington’s disease. This disease model, one of the first of its kind to be commercially available, accurately reflects the genetics of the disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220508005024/en/
bit.bio's ioGlutamatergic Neurons HTT50CAG/WT - this is an image of our ioGlutamatergic Neurons carrying the disease-relevant 50 CAG trinucleotide repeat expansion, associated with Huntington’s disease. Image credit: Origami Therapeutics and Scintillant Bioscience (Photo: Business Wire)
This is the pioneer product from bit.bio’s new ioDisease Model portfolio, a range of cells which have specific disease-associated mutations, that can replicate human diseases in vitro andcan be matched to an isogenic wild type control. The cells are induced pluripotent stem cell (iPSC)-derived, generated using bit.bio’s opti-oxTM1 precision cellular reprogramming technology in combination with CRISPR/Cas9-based gene editing.
Huntington’s disease is an inherited neurodegenerative condition that affects approximately 5 to 10 out of every 100,000 people2. It is caused by specific mutations in the huntingtin gene, specifically ≥ 40 repeats of a ‘CAG’ DNA sequence. The mutation negatively impacts a range of neuronal cells in the brain, resulting in irreversible damage.
There is no known cure for Huntington’s disease, and the precise underlying mechanisms remain poorly understood. There are limited treatment options for patients that only minimise the impact of symptoms. Until now, it has been difficult for scientists to engineer the specific disease-causing mutation in cells. Having the right disease model can facilitate the study of potential mechanisms and identify therapeutic approaches.
By introducing a stable 50 ‘CAG’ repeat mutation in the Huntingtin gene in wild type ioGlutamatergic Neurons, bit.bio have developed a consistent, scalable cell model that replicates the disease in vitro. Their ability to rapidly mature to glutamatergic neurons, along with their unprecedented scalability and batch-to-batch reproducibility, also makes them ideally suited to high-throughput screening applications.
Using ioGlutamatergic Neurons HTT50CAG/WTand wild type ioGlutamatergic Neurons (that do not possess the mutation) in drug discovery allows the life science community to study the effects of novel treatments in a disease-relevant system with a genetically matched control. Being able to compare data from the disease cell model to those of the genetically matched control offers the potential to identify and investigate the effects of the CAG trinucleotide repeat expansion.
Dr Mark Kotter, CEO and Founder at bit.bio, said: “bit.bio's mission is coding cells for novel cures. The launch of our Huntington's disease model provides the industry with an advanced cellular tool to support the study of a devastating condition with high unmet clinical needs. Our opti-ox technology allows the development of consistent and scalable biological standards that can support the evolution of a new generation of medicines. It adds depth to our broadening R&D cell type product pipeline, each product will transition to its own product line.”
Dr Farah Patell-Socha, VP Research Products, at bit.bio, said: “ioGlutamatergic Neurons HTT 50CAG/WT is the first in a series of neurodegenerative disease models being launched by bit.bio, providing a reliable, commercially available source of consistent and scalable cells. By offering more physiologically relevant disease mutations, the disease model portfolio has the potential to help address current gaps facing the successful translation of research into the clinic, crucially by providing isogenic cell models we are delivering a solution that has the potential to boost drug discovery and development.”
bit.bio’s precision cellular reprogramming technology, opti-ox, enables the controlled reprogramming of entire cultures of stem cells into any cell type. This overcomes the inherent limitations of classical cell generation methods and allows the reproducible production of human cells within days, at an industrial scale.
- ENDS -
Notes to Editors
bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines.
This is possible with our precision cellular reprogramming technology, opti-ox™ - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells.
bit.bio was founded in 2016 by Dr Mark Kotter from his labs at Cambridge University after his discovery of the opti-ox technology. Co-founder Florian Schuster joined in 2018 as the company continued to grow and develop.
The company now has over 130 employees and is headquartered in Cambridge, UK and San Francisco, US.
In July 2019, the company announced the closure of a $45m Series A fundraise, followed by $103 million in its first close of Series B financing in November 2021.
The company recently expanded its board to include:
● Dr Hermann Hauser, serial entrepreneur, co-founder of Amadeus Capital Partners and founder of semiconductor company, Arm Ltd, and gene-sequencing company, Solexa / Illumina, joins as chair of the board.
● Sir Greg Winter, Nobel-winning scientist, and known for his work on monoclonal antibodies, is the founder of multiple successful biotech companies.
● Alan S. Roemer, biotechnology entrepreneur who launched Pharmasset and Roivant Sciences, has raised over $1.75 billion in private and public capital and consummated five IPOs
For more information visit bit.bio
opti-ox and ioDisease Model are trademarks of bit.bio
- Pawlowski, M. et al. Inducible and Deterministic Forward Programming of Human Pluripotent Stem Cells into Neurons, Skeletal Myocytes, and Oligodendrocytes. Stem Cell Reports 8, 803–812 (2017).
- Yohrling G, Raimundo K, Crowell V, Lovecky D, Vetter L, Seeberger L: Prevalence of Huntington’s disease in the US (954). In: AAN Enterprises, (2020).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220508005024/en/
Copyright Business Wire 2022